Synovial sarcoma: Recent discoveries as a roadmap to new avenues for therapy

Cancer Discovery

Volumn 5, Issue 2, 2015, Pages 124-134

  Nielsen, Torsten O ^a   Poulin, Neal M ^a   Ladanyi, Marc ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 AMINO 5 BENZOXAZOLYL) 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 AMINE; ACTIVATING TRANSCRIPTION FACTOR 2; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BETA CATENIN; CANCER TESTIS ANTIGEN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; ID LV305; IFOSFAMIDE; LGK974; MAMMALIAN TARGET OF RAPAMYCIN; N (6, 7 DIHYDRO 6 OXO 5H DIBENZ [B, D] AZEPIN 7 YL) 2, 2 DIMETHYL N' (2, 2, 3, 3, 3 PENTAFLUOROPROPYL) PROPANEDIAMIDE; NOTCH RECEPTOR; OTSA101; PAZOPANIB; PENTETIC ACID; PROTEIN KINASE B; PROTEIN SWI; REGORAFENIB; TEMSIROLIMUS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNF; TRANSDUCIN LIKE ENHANCER OF SPLIT 1; UNCLASSIFIED DRUG; VISMODEGIB; VORINOSTAT; YTTRIUM 90; TUMOR PROTEIN;

CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME TRANSLOCATION 18; CHROMOSOME TRANSLOCATION X; CINICAL FEATURE; DRUG TARGETING; EPIGENETIC REPRESSION; GENE; GENE EXPRESSION; GENE FUSION; GENE MUTATION; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; NUCLEOSOME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SS18 GENE; SSX1 GENE; SSX2 GENE; SYNOVIAL SARCOMA; WNT SIGNALING PATHWAY; ANIMAL; GENE TRANSLOCATION; GENETICS; METABOLISM; PATHOLOGY; SARCOMA, SYNOVIAL;

ANIMALS; HUMANS; NEOPLASM PROTEINS; SARCOMA, SYNOVIAL; TRANSLOCATION, GENETIC;

EID: 84922377618     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-1246     Document Type: Review

References (79)

1. Herzog CE. Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol 2005; 27: 215-8.
2. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002; 62: 135-40.
3. Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer 2009; 115: 3537-47.
4. Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 2005; 16: 437-44.
5. Al-Hussaini H, Hogg D, Blackstein ME, O'Sullivan B, Catton CN, Chung PW, et al. Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma 2011; 2011: 231789.
6. Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18) (p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994; 7: 502-8.
7. Skytting B, Nilsson G, Brodin B, Xie Y, Lundeberg J, Uhlen M, et al. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst 1999; 91: 974-5.
8. Panagopoulos I, Mertens F, Isaksson M, Limon J, Gustafson P, Skytting B, et al. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer 2001; 31: 362-72.
9. Joseph CG, Hwang H, Jiao Y, Wood LD, Kinde I, Wu J, et al. Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes Cancer 2014; 53: 15-24.
10. Carmody Soni EE, Schlottman S, Erkizan HV, Uren A, Toretsky JA. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma. Clin Orthop Relat Res 2014; 472: 874-82.
11. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007; 11: 375-88.
12. Brett D, Whitehouse S, Antonson P, Shipley J, Cooper C, Goodwin G. The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies. Hum Mol Genet 1997; 6: 1559-64.
13. Perani M, Antonson P, Hamoudi R, Ingram CJ, Cooper CS, Garrett MD, et al. The proto-oncoprotein SYT interacts with SYT-interacting protein/co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteins. J Biol Chem 2005; 280: 42863-76.
14. Thaete C, Brett D, Monaghan P, Whitehouse S, Rennie G, Rayner E, et al. Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum Mol Genet 1999; 8: 585-91.
15. Kato H, Tjernberg A, Zhang W, Krutchinsky AN, An W, Takeuchi T, et al. SYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histones. J Biol Chem 2002; 277: 5498-505.
16. Middeljans E, Wan X, Jansen PW, Sharma V, Stunnenberg HG, Logie C. SS18 together with animal-specific factors defines human BAFtype SWI/SNF complexes. PLoS ONE 2012; 7: e33834.
17. Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 2013; 153: 71-85.
18. Jackson EM, Sievert AJ, Gai X, Hakonarson H, Judkins AR, Tooke L, et al. Genomic analysis using high-density single nucleotide polymorphismbased oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin Cancer Res 2009; 15: 1923-30.
19. Le Loarer F, Zhang L, Fletcher CD, Ribeiro A, Singer S, Italiano A, et al. Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. Genes Chromosomes Cancer 2014; 53: 475-86.
20. Wang X, Sansam CG, Thom CS, Metzger D, Evans JA, Nguyen PT, et al. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res 2009; 69: 8094-101.
21. Mueller-Planitz F, Klinker H, Becker PB. Nucleosome sliding mechanisms: new twists in a looped history. Nat Struct Mol Biol 2013; 20: 1026-32.
22. Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 2013; 45: 592-601.
23. Tolstorukov MY, Sansam CG, Lu P, Koellhoffer EC, Helming KC, Alver BH, et al. Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proc Natl Acad Sci U S A 2013; 110: 10165-70.
24. Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b- ARF-INK4a locus. Mol Cell Biol 2008; 28: 3457-64.
25. Guan B, Wang TL, Shih Ie M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011; 71: 6718-27.
26. Watanabe R, Ui A, Kanno S, Ogiwara H, Nagase T, Kohno T, et al. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability. Cancer Res 2014; 74: 2465-75.
27. Soulez M, Saurin AJ, Freemont PS, Knight JC. SSX and the synovialsarcoma- specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex. Oncogene 1999; 18: 2739-46.
28. Garcia CB, Shaffer CM, Eid JE. Genome-wide recruitment to Polycombmodified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2. BMC Genomics 2012; 13: 189.
29. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005; 65: 9226-35.
30. Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de Rijn M, et al. Histone deacetylase inhibitors reverse SS18-SSXmediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 2008; 68: 4303-10.
31. Ito T, Ouchida M, Morimoto Y, Yoshida A, Jitsumori Y, Ozaki T, et al. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 2005; 224: 311-9.
32. Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012; 21: 333-47.
33. Levanon D, Goldstein RE, Bernstein Y, Tang H, Goldenberg D, Stifani S, et al. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci U S A 1998; 95: 11590-5.
34. Grbavec D, Stifani S. Molecular interaction between TLE1 and the carboxyl-terminal domain of HES-1 containing the WRPW motif. Biochem Biophys Res Commun 1996; 223: 701-5.
35. Nakayama R, Mitani S, Nakagawa T, Hasegawa T, Kawai A, Morioka H, et al. Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol 2010; 34: 1599-607.
36. Valente AL, Tull J, Zhang S. Specificity of TLE1 expression in unclassified high-grade sarcomas for the diagnosis of synovial sarcoma. Appl Immunohistochem Mol Morphol 2013; 21: 408-13.
37. Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol 2009; 33: 1743-51.
38. Saito T, Nagai M, Ladanyi M. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Res 2006; 66: 6919-27.
39. Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K, et al. Synovial sarcoma is a stem cell malignancy. Stem Cells 2010; 28: 1119-31.
40. Haldar M, Hedberg ML, Hockin MF, Capecchi MR. A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. Cancer Res 2009; 69: 3657-64.
41. Hayakawa K, Ikeya M, Fukuta M, Woltjen K, Tamaki S, Takahara N, et al. Identification of target genes of synovial sarcoma-associated fusion oncoprotein using human pluripotent stem cells. Biochem Biophys Res Commun 2013; 432: 713-9.
42. Wakamatsu T, Naka N, Sasagawa S, Tanaka T, Takenaka S, Araki N, et al. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma. Cancer Sci 2014; 105: 1124-34.
43. Yasui H, Naka N, Imura Y, Outani H, Kaneko K, Hamada K, et al. Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001. Cancer Lett 2014; 347: 114-22.
44. Lagarde P, Przybyl J, Brulard C, Perot G, Pierron G, Delattre O, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol 2013; 31: 608-15.
45. Przybyl J, Sciot R, Wozniak A, Schoffski P, Vanspauwen V, Samson I, et al. Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. Int J Biochem Cell Biol 2014; 53: 505-13.
46. Schneider-Stock R, Onnasch D, Haeckel C, Mellin W, Franke DS, Roessner A. Prognostic significance of p53 gene mutations and p53 protein expression in synovial sarcomas. Virchows Arch 1999; 435: 407-12.
47. Oda Y, Sakamoto A, Satio T, Kawauchi S, Iwamoto Y, Tsuneyoshi M. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Mod Pathol 2000; 13: 994-1004.
48. Ito M, Barys L, O'Reilly T, Young S, Gorbatcheva B, Monahan J, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res 2011; 17: 416-26.
49. Saito T, Oda Y, Kawaguchi K, Takahira T, Yamamoto H, Tanaka K, et al. PTEN and other tumor suppressor gene mutations as secondary genetic alterations in synovial sarcoma. Oncol Rep 2004; 11: 1011-5.
50. Subramaniam MM, Calabuig-Farinas S, Pellin A, Llombart-Bosch A. Mutational analysis of E-cadherin, beta-catenin and APC genes in synovial sarcomas. Histopathology 2010; 57: 482-6.
51. Saito T, Oda Y, Sakamoto A, Kawaguchi K, Tanaka K, Matsuda S, et al. APC mutations in synovial sarcoma. J Pathol 2002; 196: 445-9.
52. Ho AL, Vasudeva SD, Lae M, Saito T, Barbashina V, Antonescu CR, et al. PDGF receptor alpha is an alternative mediator of rapamycininduced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res 2012; 72: 4515-25.
53. Friedrichs N, Trautmann M, Endl E, Sievers E, Kindler D, Wurst P, et al. Phosphatidylinositol-3′-kinase/AKT signaling is essential in synovial sarcoma. Int J Cancer 2011; 129: 1564-75.
54. Nagayama S, Fukukawa C, Katagiri T, Okamoto T, Aoyama T, Oyaizu N, et al. Therapeutic potential of antibodies against FZD 10, a cellsurface protein, for synovial sarcomas. Oncogene 2005; 24: 6201-12.
55. Ishibe T, Nakayama T, Aoyama T, Nakamura T, Toguchida J. Neuronal differentiation of synovial sarcoma and its therapeutic application. Clin Orthop Relat Res 2008; 466: 2147-55.
56. Jungbluth AA, Antonescu CR, Busam KJ, Iversen K, Kolb D, Coplan K, et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 2001; 94: 252-6.
57. Guo W, Gorlick R, Ladanyi M, Meyers PA, Huvos AG, Bertino JR, et al. Expression of bone morphogenetic proteins and receptors in sarcomas. Clin Orthop Relat Res 1999; 365: 175-83.
58. Nielsen TO, Hsu FD, O'Connell JX, Gilks CB, Sorensen PH, Linn S, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 2003; 163: 1449-56.
59. Pelmus M, Guillou L, Hostein I, Sierankowski G, Lussan C, Coindre JM. Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am J Surg Pathol 2002; 26: 1434-40.
60. Cajaiba MM, Jianhua L, Goodman MA, Fuhrer KA, Rao UN. Sox9 expression is not limited to chondroid neoplasms: variable occurrence in other soft tissue and bone tumors with frequent expression by synovial sarcomas. Int J Surg Pathol 2010; 18: 319- 23.
61. Ishibe T, Nakayama T, Okamoto T, Aoyama T, Nishijo K, Shibata KR, et al. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin Cancer Res 2005; 11: 2702-12.
62. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010; 42: 715-21.
63. Saito T, Oda Y, Sakamoto A, Tamiya S, Kinukawa N, Hayashi K, et al. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol 2000; 192: 342-50.
64. Horvai AE, Kramer MJ, O'Donnell R. Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med 2006; 130: 792-8.
65. Ng TL, Gown AM, Barry TS, Cheang MC, Chan AK, Turbin DA, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005; 18: 68-74.
66. Barham W, Frump AL, Sherrill TP, Garcia CB, Saito-Diaz K, VanSaun MN, et al. Targeting the Wnt pathway in synovial sarcoma models. Cancer Discov 2013; 3: 1286-301.
67. Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, et al. SS18-SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene 2013; 33: 5006-16.
68. Proffitt KD, Madan B, Ke Z, Pendharkar V, Ding L, Lee MA, et al. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res 2013; 73: 502-7.
69. Rosenbluh J, Wang X, Hahn WC. Genomic insights into WNT/betacatenin signaling. Trends Pharmacol Sci 2014; 35: 103-9.
70. Michels S, Trautmann M, Sievers E, Kindler D, Huss S, Renner M, et al. SRC signaling is crucial in the growth of synovial sarcoma cells. Cancer Res 2013; 73: 2518-28.
71. Mora-Blanco EL, Mishina Y, Tillman EJ, Cho YJ, Thom CS, Pomeroy SL, et al. Activation of beta-catenin/TCF targets following loss of the tumor suppressor SNF5. Oncogene 2014; 33: 933-8.
72. Teng HW, Wang HW, Chen WM, Chao TC, Hsieh YY, Hsih CH, et al. Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. J Surg Oncol 2011; 103: 773- 81.
73. Bozzi F, Ferrari A, Negri T, Conca E, Luca da R, Losa M, et al. Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation. Transl Oncol 2008; 1: 95-101.
74. Setsu N, Kohashi K, Fushimi F, Endo M, Yamamoto H, Takahashi Y, et al. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma. Cancer 2013; 119: 3504-13.
75. Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, et al. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer 2014; 61: 1486-9.
76. Antonescu CR, Kawai A, Leung DH, Lonardo F, Woodruff JM, Healey JH, et al. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol 2000; 9: 1-8.
77. Krskova L, Kalinova M, Brizova H, Mrhalova M, Sumerauer D, Kodet R. Molecular and immunohistochemical analyses of BCL2, KI-67, and cyclin D1 expression in synovial sarcoma. Cancer Genet Cytogenet 2009; 193: 1-8.
78. Jones KB, Su L, Jin H, Lenz C, Randall RL, Underhill TM, et al. SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. Oncogene 2013; 32: 2365-71.
79. Kawaguchi S, Tsukahara T, Ida K, Kimura S, Murase M, Kano M, et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group. Cancer Sci 2012; 103: 1625-30.